



HAE runs in their family. So could the

TAKHZYRO EXPERIENCE

Join the 4,000+ people since 2018* who have chosen to help prevent hereditary angioedema (HAE) attacks before they happen.

*Based on third-party US specialty pharmacy data for adolescent and adult patients.

WHAT IS TAKHZYRO?

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older.

It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- chest tightness
- faintness
- hives
- difficulty breathing
- fast heartbeat
- rash

Please see additional **Important Safety Information** throughout and full **Prescribing Information**, including information for patients.


TAKHZYRO[®]
(lanadelumab-flyo) injection 300mg·150mg

DOES YOUR FAMILY SHARE THE HAE GENE?

Every family has shared genes

Maybe it's the red hair gene or the height gene. Some families also share the HAE gene. Because HAE is genetic, it can be passed down through generations. **If you or a loved one has HAE, it could mean other members of your family have HAE as well.**

HAE can be an unpredictable condition for your family

If you or someone in your family has HAE, it's hard to say when the next attack will happen. Or what part of the body it will affect. In fact, some children with HAE may not have their first attack until they are older.



The symptoms of HAE may change in frequency and severity over time



HAE attacks can be unpredictable, debilitating, and potentially life-threatening (throat attacks)—even for children



Ask your doctor if TAKHZYRO should be considered as part of your long-term HAE management plan

The 2020 US Hereditary Angioedema Association (HAEA) guidelines recommend:

- Regular review of any HAE management plan. This includes the consideration of long-term preventive treatment in children and adults
- TAKHZYRO as one of the first-line treatments for long-term prevention of HAE attacks in people 12 years of age and older



Patient portrayal.

IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088.

Please see additional **Important Safety Information** throughout and full **Prescribing Information**, including information for patients.

TAKHZYRO[®]
(lanadelumab-flyo) injection 300mg-150mg

WHEN HAE RUNS IN THE FAMILY, TAKHZYRO MAY BE AN OPTION

TAKHZYRO is the first and only preventive treatment indicated for children with HAE 2 years of age and older. This means it could be a preventive option for you and your family members with HAE.



TAKHZYRO is the #1 prescribed HAE preventive treatment*



Prescribed to 4,000+ people since 2018†



Established safety profile from a 26-week study of 125 adults and adolescents (≥ 12 years of age) with HAE and a 52-week study of 21 children (2 to <12 years of age) with HAE



Dosing once every 2 weeks for people 6 years of age and up, or every 4 weeks for children 2 to <6 years of age

When multiple members of the family are on TAKHZYRO, you can all navigate your treatment journey together.

*Based on total patients on HAE preventive treatments according to US third-party industry healthcare data.

†The number of patients prescribed TAKHZYRO is based on third-party US specialty pharmacy data.

To sign up for more information about TAKHZYRO, visit TAKHZYRO.com/letsconnect.



Patient portrayal.

IMPORTANT SAFETY INFORMATION (cont'd)

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

Please see additional **Important Safety Information** throughout and full **Prescribing Information**, including information for patients.

TAKHZYRO[®]
(lanadelumab-flyo) injection 300mg-150mg



Patient portrayal.

IMPORTANT SAFETY INFORMATION (cont'd)

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- difficulty breathing
- chest tightness
- fast heartbeat
- faintness
- rash
- hives

TAKHZYRO WAS PROVEN EFFECTIVE IN ADOLESCENTS AND ADULTS

The 6.5-month clinical study included 125 people diagnosed with HAE aged 12 years and older. The main goal of the study was to evaluate the ability of TAKHZYRO 300 mg every 2 weeks to reduce the frequency of HAE attacks.

On average, people had

87% FEWER ATTACKS
compared with placebo
(average monthly attack rate of 0.3 vs 2.0)

of people
44% HAD ZERO ATTACKS
for the entire 6.5-month study
compared with 2% of those taking placebo

Established safety results

The most common side effects in the 6.5-month clinical study were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches.

All data presented are for TAKHZYRO 300 mg every 2 weeks unless otherwise indicated.

Please see additional [Important Safety Information](#) throughout and full [Prescribing Information](#), including information for patients.

TAKHZYRO[®]
(lanadelumab-flyo) injection 300mg-150mg

TAKHZYRO WAS STUDIED IN CHILDREN

The largest pediatric trial of any preventive treatment in HAE

The 52-week, open-label study included 21 children diagnosed with HAE aged 2 to <12 years. The main goals of the study were to:



Evaluate the safety of TAKHZYRO 150 mg taken once every 2 weeks or every 4 weeks



Measure levels of TAKHZYRO in the body for children 2 to <12 years of age

In the 52-week study, there were:

- No serious side effects reported
- No discontinuations due to side effects
- No allergic reactions related to TAKHZYRO

In addition, levels of TAKHZYRO in the body for children 2 to <12 years of age who received 150 mg every 2 or 4 weeks were similar to those in adult patients receiving TAKHZYRO 300 mg every 2 weeks.

IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088.

Most common related side effects in children taking TAKHZYRO 150 mg every 2 or 4 weeks (21 children)

- Injection site pain: **29%**
- Administration site pain: **5%**
- Injection site redness: **14%**
- Injection site reaction: **5%**
- Injection site swelling: **5%**



“What an exciting day it was to learn that TAKHZYRO was approved for children 2 years of age and older. My daughter and I have a lot in common—including our treatment plan.”

— **Eric**, a real HAE patient

His TAKHZYRO experience started in 2018

Please see additional [Important Safety Information](#) throughout and full [Prescribing Information](#), including information for patients.

TAKHZYRO[®]
(lanadelumab-flyo) injection 300mg-150mg

ESTABLISHED EFFECTIVENESS OF TAKHZYRO IN CHILDREN

Use of TAKHZYRO in children 2 to <12 years of age was supported by:

- Efficacy data from the 6.5-month study in people 12 years of age and older
- Additional data that showed similar levels of TAKHZYRO were reached in the body for adults and children

A secondary goal of the 52-week study was to measure the ability of TAKHZYRO 150 mg taken once every 2 weeks or every 4 weeks to prevent HAE attacks in 21 children 2 to <12 years of age. Decrease in HAE attacks was measured as the number of attacks before the patient started in the study compared to the number of HAE attacks after taking TAKHZYRO.

An important note about this study

The study was not designed to understand how well TAKHZYRO works in children. The 21 children included knew they were taking TAKHZYRO. This study did not compare TAKHZYRO to another product or placebo. These details make it difficult to determine how well TAKHZYRO decreased HAE attacks in children.

On average, children had:

- **95%** fewer HAE attacks compared to before starting the study
- **76%** of children were attack free for the entire 52-week study

IMPORTANT SAFETY INFORMATION (cont'd)

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.



Patient portrayal.

To learn more about TAKHZYRO for your loved ones, visit TAKHZYRO.com/why-takhzyro/takhzyro-for-loved-ones.

Please see additional **Important Safety Information** throughout and full **Prescribing Information**, including information for patients.

TAKHZYRO[®]
(lanadelumab-flyo) injection 300mg-150mg

Adults and adolescents (≥12 years of age)

FREEDOM FROM DAILY DOSING

ABOUT **1 MINUTE TO SELF-INJECT**

for most people in the clinical studies*

- TAKHZYRO is a plasma-free, subcutaneous (under-the-skin) injection that you give yourself

*Most adolescents and adults in the clinical studies self-administered TAKHZYRO within 10 to 60 seconds. These injection times are based on vial administration.

2 WEEKS BETWEEN EACH DOSE

for people 12 years of age and older

- The recommended starting dose for people 12 years of age and older is 300 mg every 2 weeks
- It takes about 6 doses of TAKHZYRO for the amount of medication to become constant in your body
- If you experience zero attacks for more than 6 months, your doctor may consider prescribing TAKHZYRO 300 mg every 4 weeks



Before starting treatment with TAKHZYRO, you will receive training to ensure you know how to administer your therapy. **Do not attempt to take TAKHZYRO without first being trained by a healthcare provider.**

IMPORTANT SAFETY INFORMATION (cont'd)

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- difficulty breathing
- chest tightness
- fast heartbeat
- faintness
- rash
- hives

"With TAKHZYRO, I've gone up to a year without an attack."[†]

— **Andrew**, a real HAE patient
His TAKHZYRO experience started in 2018

Individual results may vary.

[†]In the 2.5-year open-label extension study, which included 212 people with HAE 12 years of age and older, safety was the primary focus. In this study, 69% of people taking TAKHZYRO 300 mg every 2 weeks had zero attacks for up to a year. "Open-label" means people knew they were taking TAKHZYRO.

To download helpful resources, visit TAKHZYRO.com/support-resources.

Please see additional **Important Safety Information** throughout and full **Prescribing Information**, including information for patients.

TAKHZYRO[®]
(lanadelumab-flyo) injection 300mg-150mg

DOSING THAT FITS IN YOUR CHILD'S LIFE

When it comes to your child's HAE treatment, it helps if the dosing schedule works with their lifestyle.

TAKHZYRO is a subcutaneous (under-the-skin) injection you or a healthcare professional can administer to your child.

Here's what you need to know about dosing with TAKHZYRO:

Recommended dosages

For children 2 to <6 years of age, 150 mg every

4 WEEKS

For children 6 to <12 years of age, 150 mg every

2 WEEKS

- If your child is taking TAKHZYRO every 2 weeks and is well controlled (for example, experiencing zero attacks for more than 6 months), their doctor may consider switching them to every 4 weeks

Administration

3 CHOICES FOR INJECTION SITE

stomach, thigh, or upper arm

≤1 MINUTE TO INJECT

for people 12 years of age and older*

IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088.

Do not attempt to administer TAKHZYRO without first being trained by a healthcare provider. You will receive training once your child is prescribed TAKHZYRO.

Administer your child's medicine with the single-dose, ready-to-use prefilled syringe.



Not actual size.



"I really like the fact that my daughter and I are taking the same preventive treatment. Already being familiar with the administration process of TAKHZYRO is such a comfort."

— **SynToia**, a real HAE patient
Her TAKHZYRO experience started in 2021

*Most adolescents and adults in the clinical studies self-administered TAKHZYRO within 10 to 60 seconds. These injection times are based on vial administration.



Sign up for dosing reminders for you and your family by texting SIGNUP (o RECORDAR en español) to 36395.*

*Message and data rates may apply. Average of 3 messages per month. Text HELP to 36395 for more information, or text STOP to 36395 to end text reminders. View our Terms & Conditions at engagedrx.com/tak.

Please see additional **Important Safety Information** throughout and full **Prescribing Information**, including information for patients.

TAKHZYRO
(lanadelumab-flyo) injection 300mg-150mg



Supporting patients with HAE for over 16 years



Takeda Patient Support offers tailored support for TAKHZYRO® (lanadelumab-flyo). We understand that living with HAE looks different for everyone. Our long-term commitment to the HAE community allows us to better understand and meet your needs.



Our support specialists are here to address your questions and help get you the resources you need. Some of the resources we offer include:

- 🔄 **Enrolling** you in the **Takeda Patient Support Co-Pay Assistance Program**, if you qualify*
- 🔄 **Working** with your specialty pharmacy to **help you receive TAKHZYRO**
- 🔄 **Arranging** for **in-home injection training** from a specially trained nurse
- 🔄 **Navigating** the **health insurance** process, along with help accessing financial insurance. Eligible patients can have their co-pays covered at 100%, up to the program maximum*
- 🔄 **Directing** you to **community support resources and education**

To learn more about Takeda Patient Support, visit www.takedapatientssupport.com.

You can also call 1-866-888-0660
Monday through Friday, 8:30 AM to 8 PM ET.

*To be eligible, you must be enrolled in Takeda Patient Support and have commercial insurance. Other terms and conditions apply. Call us for more details.

Please see additional [Important Safety Information](#) throughout and full [Prescribing Information](#), including information for patients.

IMAGINE THE TAKHZYRO EXPERIENCE

For you or your family members

Prescribed to

4,000+

people since 2018*
who have chosen
TAKHZYRO to help
prevent HAE attacks

Fewer HAE attacks
were experienced by

87%

of 125 adults
and adolescents
for 6.5 months

Takeda has
more than

16+

years of experience
supporting people with
HAE and their caregivers

*Based on third-party US specialty pharmacy data for adolescent and adult patients.

Hear more from others with HAE.
Visit TAKHZYRO.com/patient-stories.

WHAT IS TAKHZYRO?

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older.

It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- chest tightness
- faintness
- hives
- difficulty breathing
- fast heartbeat
- rash

Please see additional [Important Safety Information](#) throughout and full [Prescribing Information](#), including information for patients.



©2025 Takeda Pharmaceuticals U.S.A., Inc., 500 Kendall Street, Cambridge, MA 02142. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. Takeda, , and  are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. TAKHZYRO is a registered trademark of Dyax Corp. US-LANA-2348v1.0 06/25

Visit us on:



TAKHZYRO
(lanadelumab-flyo) injection 300mg-150mg